Statin therapy and the incidence of atherosclerotic cardiovascular events after kidney transplantation

被引:1
|
作者
Nazoiri, Charifa [1 ]
Liabeuf, Sophie [1 ,2 ]
Brazier, Francois [2 ,3 ]
Nowak, Alban [1 ]
Bennis, Youssef [2 ]
Laville, Solene M. [1 ,2 ]
Bodeau, Sandra [1 ,2 ]
Gras-Champel, Valerie [1 ,2 ]
Masmoudi, Kamel [1 ]
Choukroun, Gabriel [2 ,3 ]
Batteux, Benjamin [1 ,2 ,4 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, Amiens, France
[2] Jules Verne Univ Picardie, MP3CV Lab, EA7517, Amiens, France
[3] Amiens Univ, Dept Nephrol Internal Med Dialysis Transplantat, Med Ctr, Amiens, France
[4] St Quentin Med Ctr, Dept Rheumatol, St Quentin en Yvelines, France
关键词
cardiovascular events; kidney transplant recipients; pharmacoepidemiology; pharmacovigilance; statins; CLINICAL-PRACTICE GUIDELINE; ADVERSE DRUG-REACTIONS; CARDIAC OUTCOMES; ECONOMIC BURDEN; DISEASE; RECIPIENTS; CYCLOSPORINE; MORTALITY; EPIDEMIOLOGY; ATORVASTATIN;
D O I
10.1093/ndt/gfad217
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Statins are recommended in kidney transplant recipients (KTRs)-a population with a high risk of major cardiovascular (CV) events. However, the literature data on the effectiveness of statins in KTRs are sparse and inconclusive. The present study's objective was to evaluate the association between statin exposure and atherosclerotic CV events in KTRs and the biochemical effectiveness of statins on the lipid profile. Methods. A total of 318 consecutive KTRs managed at a single center between 2006 and 2019 were retrospectively included. Those exposed to statins after transplantation were incident users. In all users, statins were indicated for primary CV prevention. Lipid profiles, the occurrence of any atherosclerotic CV events (stroke, myocardial infarction, other atherosclerotic CV events and atherosclerotic CV deaths) were documented comprehensively. We applied Cox models that included statin exposure as a time-dependent covariate fitted with time-varying inverse probability treatment weighting (IPTW) to assess the effectiveness of statins on atherosclerotic CV events and on all CV events. We built linear mixed models to assess the biochemical effectiveness of statins. Results. During a median (interquartile range) follow-up period of 6.0 (3.9-10.0) years, 27 atherosclerotic CV events occurred in 26 patients. In the Cox models fitted with time-varying IPTW, exposure to statins was not associated with a decrease in atherosclerotic CV events; the hazard ratio was 1.16 (95% confidence interval 0.53-2.53) (P = .700). In the linear mixed models, statin exposure was associated with significant decrease over time in triglyceride and low-density lipoprotein cholesterol concentrations (P < .001). These results were consistent when stratified for the intensity of statin therapy. Conclusion. Even though the lipid profile improved, statin exposure was not associated with a decrease in CV events in this real-life, single-center, retrospective, long-term follow-up study of a KTR cohort. Larger, controlled studies are needed to confirm or refute these results.
引用
收藏
页码:818 / 829
页数:12
相关论文
共 50 条
  • [31] Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
    Bae, Sunjae
    Ahn, JiYoon B.
    Joseph, Corey
    Whisler, Ryan
    Schnitzler, Mark A.
    Lentine, Krista L.
    Kadosh, Bernard S.
    Segev, Dorry L.
    McAdams-DeMarco, Mara A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (05): : 626 - 633
  • [32] LIPOPROTEIN(A) AND THE RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR EVENTS AMONG ADULTS WITH CHRONIC KIDNEY DISEASE AND A HISTORY OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Poudel, Bharat
    Rosenson, Robert S.
    Kent, Shia
    Bittner, Vera
    Gutierrez, Orlando
    Anderson, Amanda H.
    Woodward, Mark
    Jackson, Elizabeth A.
    Monda, Keri L.
    Bajaj, Archna
    Huang, Lei
    Rader, Daniel J.
    Kansal, Mayank
    Rahman, Mahboob
    He, Jiang
    Muntner, Paul
    Colantonio, Lisandro
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1511 - 1511
  • [33] Safety of Statin Therapy After Liver Transplantation
    Glynn, M.
    Jantz, A.
    Summers, B.
    Salgia, R.
    Sulejmani, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 585 - 585
  • [34] Continuation of Statin Therapy and Primary Prevention of Nonfatal Cardiovascular Events
    Shalev, Varda
    Goldshtein, Inbal
    Porath, Avi
    Weitzman, Dahlia
    Shemer, Joshua
    Chodick, Gabriel
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (12): : 1779 - 1786
  • [35] The Incidence of Cardiovascular and Cerebrovascular Events Associated With Sirolimus Use After Liver Transplantation.
    Chacra, W.
    Weick, A.
    Kuchipudi, A.
    Elbatta, M.
    Divine, G.
    Barth, C.
    Moonka, D.
    TRANSPLANTATION, 2014, 98 : 161 - 161
  • [36] The Incidence of Cardiovascular and Cerebrovascular Events Associated With Sirolimus Use After Liver Transplantation.
    Chacra, W.
    Weick, A.
    Kuchipudi, A.
    Elbatta, M.
    Divine, G.
    Barth, C.
    Moonka, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 161 - 161
  • [37] The incidence of cancer after kidney transplantation
    Contillo, Christine
    Lindsey, Heather
    Price, Cynthia
    Chu, Julie
    AMERICAN JOURNAL OF NURSING, 2008, 108 (05) : 72G - 72H
  • [38] Incidence of malignancies after kidney transplantation
    Keller, H
    Igna, D
    Kirste, G
    Farthmann, EH
    LANGENBECKS ARCHIV FUR CHIRURGIE, 1996, : 1247 - 1247
  • [39] Acute Kidney Injury and Long-Term Risk for Cardiovascular Events in Patients after Kidney Transplantation
    Rahamimov, Ruth
    van Dijk, Tuvia Y.
    Molcho, Maya
    Vahav, Itay
    Mor, Eytan
    Ben Dor, Naomy
    Goldman, Shira
    Rozen-Zvi, Benaya
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (05): : 1149 - 1157
  • [40] Scoring of medial arterial calcification predicts cardiovascular events and mortality after kidney transplantation
    Erlandsson, Helen
    Qureshi, Abdul Rashid
    Ripsweden, Jonaz
    Lofman, Ida Haugen
    Soderberg, Magnus
    Wennberg, Lars
    Lundgren, Torbjorn
    Bruchfeld, Annette
    Brismar, Torkel B.
    Stenvinkel, Peter
    JOURNAL OF INTERNAL MEDICINE, 2022, 291 (06) : 813 - 823